- Home
- NRSN vs IGC Comparison
NRSN vs IGC Comparison
Compare NRSN & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRSN
- IGC
- Stock Information
- Founded
- NRSN 2017
- IGC 2005
- Country
- NRSN Israel
- IGC United States
- Employees
- NRSN N/A
- IGC N/A
- Industry
- NRSN Biotechnology: Pharmaceutical Preparations
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- NRSN Health Care
- IGC Health Care
- Exchange
- NRSN Nasdaq
- IGC Nasdaq
- Market Cap
- NRSN 29.8M
- IGC 33.8M
- IPO Year
- NRSN 2021
- IGC N/A
- Fundamental
- Price
- NRSN $0.98
- IGC $0.36
- Analyst Decision
- NRSN Buy
- IGC Strong Buy
- Analyst Count
- NRSN 2
- IGC 2
- Target Price
- NRSN $14.00
- IGC $4.00
- AVG Volume (30 Days)
- NRSN 202.0K
- IGC 929.0K
- Earning Date
- NRSN 12-17-2025
- IGC 11-14-2025
- Dividend Yield
- NRSN N/A
- IGC N/A
- EPS Growth
- NRSN N/A
- IGC N/A
- EPS
- NRSN N/A
- IGC N/A
- Revenue
- NRSN N/A
- IGC $1,327,000.00
- Revenue This Year
- NRSN N/A
- IGC $3.54
- Revenue Next Year
- NRSN N/A
- IGC $15.12
- P/E Ratio
- NRSN N/A
- IGC N/A
- Revenue Growth
- NRSN N/A
- IGC 24.95
- 52 Week Low
- NRSN $0.80
- IGC $0.25
- 52 Week High
- NRSN $2.60
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- NRSN 37.32
- IGC 37.23
- Support Level
- NRSN $0.89
- IGC $0.35
- Resistance Level
- NRSN $0.97
- IGC $0.40
- Average True Range (ATR)
- NRSN 0.07
- IGC 0.03
- MACD
- NRSN -0.01
- IGC -0.00
- Stochastic Oscillator
- NRSN 26.22
- IGC 22.64
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.